In late February 2026, Merck reported a wave of positive late-stage data and regulatory milestones for KEYTRUDA-based combinations and other pipeline assets across kidney, ovarian and bladder cancers, ...

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...

MRK's Keytruda posted $31.7B in 2025 sales. Can new approvals, ongoing studies and a revamped structure keep oncology growth strong through 2026?

The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.

Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s.

Merck presents positive results from phase 3 LITESPARK-022 trial of Keytruda plus Welireg in certain patients with earlier-stage RCC at 2026 ASCO cancers symposium: Rahway, New Je ...

Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts ...

Merck MRK announced better-than-expected fourth-quarter 2025 results earlier this month. The company beat estimates for both earnings and sales. Importantly, on the fourth-quarter conference call, ...

The trial enrolled 1,841 patients and measured DFS, with safety, OS, and quality of life as secondary endpoints.

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Merck says Keytruda boosted overall survival in phase 3 ovarian cancer trial and cut death risk in bladder cancer combo data.